XML 28 R21.htm IDEA: XBRL DOCUMENT
v3.26.1

Net Loss per Share | 3 Months Ended
--- | ---
Mar. 31, 2026
Earnings Per Share [Abstract] |
Net Loss per Share | 13. Net Loss per Share Net Loss per Share Basic and diluted loss per share is computed by dividing net loss by the weighted-average common stock outstanding for the period. The Company had 15,815,253 and 15,159,753 pre-funded warrants outstanding as of March 31, 2026 and 2025, respectively. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. Due to the nominal exercise price of the pre-funded warrants, they are considered to be outstanding shares of common stock for purposes of the calculation of earnings per share. (in thousands, except for share and per share data):
|  | Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Numerator: |  |  |  |  |  |
Net loss |  | $ | (69,234 | ) |  | $ | (65,581 | )
Denominator: |  |  |  |  |  |
Weighted average common shares outstanding, basic and diluted |  |  | 81,719,016 |  |  |  | 64,986,778 |
Weighted average pre-funded warrants outstanding, basic and diluted |  |  | 15,815,253 |  |  |  | 15,159,753 |
Total weighted average common stock outstanding, basic and diluted |  |  | 97,534,269 |  |  |  | 80,146,531 |
Net loss per share: |  |  |  |  |  |
Net loss per share, basic and diluted |  | $ | (0.71 | ) |  | $ | (0.82 | )
The Company’s potentially dilutive securities, which include restricted stock and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at March 31, 2026 and 2025 because including them would have had an anti-dilutive effect:
|  | Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Unvested restricted stock |  |  | 1,535,176 |  |  |  | 1,209,989 |
Options to purchase common stock |  |  | 9,356,276 |  |  |  | 10,916,487 |
Total |  |  | 10,891,452 |  |  |  | 12,126,476 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration